Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update on January 16, 2025, from 9:45 AM to 10:25 AM PT at the Westin St. Francis in San Francisco. The presentation will highlight recent company achievements and upcoming data milestones. Institutional investors can schedule one-on-one meetings with the executives through their J.P. Morgan representatives. A webcast of the presentation will be available on the company's website in the Investor Relations section.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore della terapia al radioterapia alfa Alpha DaRT® per il cancro, ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference. Il CEO Uzi Sofer e il CFO Raphi Levy presenteranno una panoramica aziendale e un aggiornamento il 16 gennaio 2025, dalle 9:45 alle 10:25 PT presso il Westin St. Francis di San Francisco. La presentazione evidenzierà i recenti successi aziendali e i prossimi traguardi di dati. Gli investitori istituzionali possono pianificare incontri individuali con i dirigenti attraverso i loro rappresentanti J.P. Morgan. Un webcast della presentazione sarà disponibile sul sito web dell'azienda nella sezione Relazioni con gli Investitori.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la terapia de radiación alfa Alpha DaRT® para el cáncer, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan. El CEO Uzi Sofer y el CFO Raphi Levy presentarán una visión general de la empresa y una actualización el 16 de enero de 2025, de 9:45 AM a 10:25 AM PT en el Westin St. Francis de San Francisco. La presentación destacará los logros recientes de la empresa y los próximos hitos de datos. Los inversores institucionales pueden programar reuniones individuales con los ejecutivos a través de sus representantes de J.P. Morgan. Una retransmisión de la presentación estará disponible en el sitio web de la empresa en la sección de Relaciones con Inversores.
알파 타우 메디컬 (NASDAQ: DRTS)은 알파 방사선 암 치료법인 알파 다RT®의 개발업체로, 제43회 연례 J.P. 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO 우지 소퍼와 CFO 라피 레비는 2025년 1월 16일 오전 9:45부터 10:25까지 PT 시간에 샌프란시스코의 웨스틴 세인트 프란시스에서 기업 개요 및 업데이트를 제공합니다. 발표에서는 최근 회사 성과와 향후 데이터 이정표를 강조할 것입니다. 기관 투자자는 J.P. 모건 대표를 통해 경영진과 일대일 회의를 예약할 수 있습니다. 발표의 웹 캐스트는 회사 웹사이트의 투자자 관계 섹션에서 이용할 수 있습니다.
Alpha Tau Medical (NASDAQ: DRTS), développeur de la thérapie anticancéreuse par radiation alpha Alpha DaRT®, a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan sur la Santé. Le PDG Uzi Sofer et le CFO Raphi Levy présenteront un aperçu de l'entreprise et une mise à jour le 16 janvier 2025, de 9h45 à 10h25 PT au Westin St. Francis à San Francisco. La présentation mettra en lumière les réalisations récentes de l'entreprise et les prochaines étapes en matière de données. Les investisseurs institutionnels peuvent programmer des réunions individuelles avec les dirigeants par l'intermédiaire de leurs représentants J.P. Morgan. Un webinaire de la présentation sera disponible sur le site Web de l'entreprise dans la section Relations avec les Investisseurs.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der Alpha-Radiation Krebstherapie Alpha DaRT®, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. CEO Uzi Sofer und CFO Raphi Levy werden am 16. Januar 2025 von 9:45 bis 10:25 Uhr PT im Westin St. Francis in San Francisco einen Unternehmensüberblick und ein Update präsentieren. Die Präsentation wird die jüngsten Erfolge des Unternehmens und bevorstehende Datenmeilensteine hervorheben. Institutionelle Investoren können über ihre J.P. Morgan-Vertreter persönliche Meetings mit den Führungskräften vereinbaren. Ein Webcast der Präsentation wird im Investor Relations-Bereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones
JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
| Event: | J.P. Morgan 43rd Annual Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 16, 2025 |
| Time: | 9:45AM PT – 10:25AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
Webcast: Link located on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
FAQ
When is Alpha Tau (DRTS) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors access Alpha Tau's (DRTS) J.P. Morgan Conference presentation?
What topics will Alpha Tau (DRTS) cover in their J.P. Morgan Conference presentation?
How can institutional investors schedule meetings with Alpha Tau (DRTS) management at the J.P. Morgan Conference?
